Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Accesso Technology Group Share News (ACSO)
ACSO Share
Price
ACSO Share
News
ACSO Share
Chat
ACSO Share
Trades25
ACSO
Live RNS
ACSO Share
Charts
ACSO Level 2
Console
ACSO Live
Share Price
ACSO Broker
Ratings
ACSO Directors
Deals
ACSO Financial
Diary
ACSO
Fundamentals
ACSO Short
Positions
ACSO
Media
ACSO Company
Research
ACSO Company
Timeline
Share Price Information for Accesso Technology Group (ACSO)
Last checked at -
Last checked at 
Intraday Accesso Technology Group Share Chart
Wednesday broker round-up
Barclays: Berenberg reiterates buy with a target price of 220p.
Aston Martin: Citigroup reiterates buy with a target price of 2,800p.
Segro: JP Morgan reiterates neutral with a target price of 1,195p.
Sainsbury: Barclays reiterates overweight with a target price of 305p.
GlaxoSmithKline: Liberum reiterates buy with a target price of 1,700p.
On The Beach: Liberum reiterates hold with a target price of 380p.
888 Holdings: Peel Hunt reiterates buy with a target price of 500p.
Countryside Properties: Peel Hunt reiterates buy with a target price of 560p.
Redrow: Numis reiterates buy with a target price of 715p.
Accesso: Numis upgrades to buy with a target price of 800p.
International Airlines Group: Credit Suisse reiterates outperform with a target price of 256p.
Centrica: Credit Suisse reiterates outperform with a target price of 70p.
Latest ACSO News
- WINNERS & LOSERS: Evoke agrees bid; Imaging Biometrics positive trials
5 Jun 2026 - UK shareholder meetings calendar - next 7 days
20 May 2026 - accesso Technology reports strong strategic progress in uncertain year
30 Mar 2026 - UK shareholder meetings calendar - next 7 days
6 Mar 2026 - EARNINGS AND TRADING: Unigel profit surges, outlook "promising"
11 Feb 2026 - TRADING UPDATES: Henry Boot warns on 2026 profit; accesso plans tender
29 Jan 2026 - Accesso set to report year slightly ahead of expectations
29 Jan 2026 - accesso Technology shares drop as major customer terminates contract
5 Jan 2026
Related News
GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
* GSK partner Hansoh reports first late-stage data for experimental lung cancer drug
GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial
(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or ...
GSK hails 'milestone' drug trial results in China
(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip c...
Accesso Technology Group News
WINNERS & LOSERS: Evoke agrees bid; Imaging Biometrics positive trials
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Friday.
accesso Technology reports strong strategic progress in uncertain year
(Alliance News) - accesso Technology Group PLC on Monday said Chief Executive Steve Brown is stepping down as it reported a jump in annual profit and ...
EARNINGS AND TRADING: Unigel profit surges, outlook "promising"
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...
TRADING UPDATES: Henry Boot warns on 2026 profit; accesso plans tender
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Accesso set to report year slightly ahead of expectations
(Sharecast News) - Accesso Technology Group said on Thursday that it expected full-year revenue for 2025 to come in slightly ahead of market expectati...
accesso Technology shares drop as major customer terminates contract
(Alliance News) - accesso Technology Group PLC on Monday said it still expects to deliver full-year earnings in line with expectations, after a custom...
Follow the stocks
